ZYDUS LIFESCIENCES LIMITED

Zydus completes Phase II(a) study of NLRP3 inhibitor 'Usnoflast (ZYIL1)' in ALS patients, reporting therapeutic concentrations in CSF and reduced neurofilaments, with improvements in ALSFRS-R score and SVC. The study involved 24 ALS patients across 7 sites in India and will proceed to a larger Phase 2b trial. Usnoflast, an oral small molecule, has shown efficacy in pre-clinical models of neuroinflammation, Parkinson’s, IBD, and MS, and has received USFDA Orphan Drug Designation for CAPS treatment.

Zydus Lifesciences completes Phase II(a) trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor for ALS, showing proof-of-concept, favorable safety, and trends towards reduction in neurodegeneration biomarkers.

Zydus Lifesciences completes Phase II(a) trial of Usnoflast, an oral NLRP3 inflammasome inhibitor for ALS, showing therapeutic concentrations in CSF and reduced neurofilaments, with encouraging improvements in ALSFRS-R score and SVC.

Indian pharma industry to reach $130 billion by 2030, potentially $450 billion by 2047. Glenmark, Lupin, and Zydus Lifesciences stocks surged up to 100% YTD, driven by U.S. market growth and FDA approvals.

FDA approves Zituvimet XR, a sitagliptin and metformin hydrochloride extended-release tablet, for adults with type 2 diabetes, manufactured by Zydus Lifesciences Limited.